Key result
The Fib-4 index was an independent predictor of all-cause mortality and hospitalization for heart failure (HR 1.305) and correlated with HFpEF risk stratification in a subclinical population.
Why the study?
Early recognition of HFpEF during mass screening is desirable but difficult to achieve, prompting investigation into whether the Fib-4 index could serve as a screening tool.
Does the Fib-4 index predict high HFpEF risk and clinical events in a subclinical population?
Cohort (n=710)
No
Does the Fib-4 index predict high HFpEF risk and clinical events in a subclinical population?
The Fib-4 index, a simple marker of liver fibrosis, can effectively screen for high HFpEF risk and predict long-term clinical outcomes in an asymptomatic, subclinical population.
Fib-4 may aid subclinical HFpEF risk identification; hypothesis-generating and should not yet change practice.
Background and Aims: Recognition of heart failure with preserved ejection fraction (HFpEF) at an early stage in mass screening is desirable, but difficult to achieve. We examined whether the fibrosis (Fib)-4 index, a simple index of liver stiffness/fibrosis, could be used as a screening tool to select candidates requiring expert diagnostics. Methods: Individuals who participated in annual health checks between 2006 and 2007 in Arita-cho, Saga, Japan, with no history of cardiovascular disease and EF ≥ 50% were enrolled (total 710; 258 men; median age, 59 years). Conclusion: The Fib-4 index can be used to select appropriate candidates for a detailed examination of HFpEF in a subclinical population.
No takes yet. Share an insight, caveat, or question.
Okamoto et al. (2022) conducted a cohort in Subclinical population (no history of cardiovascular disease) (n=710). Fib-4 index vs. Low Fib-4 index was evaluated on Composite of all-cause mortality and hospitalization for heart failure (HR 1.305, 95% CI 1.139-1.495, p=<0.001). The Fib-4 index was an independent predictor of all-cause mortality and hospitalization for heart failure (HR 1.305) and correlated with HFpEF risk stratification in a subclinical population.
Synapse has enriched 5 related papers. Consider them for comparative context: